The Synergistic Effects of Sulfated Lactosyl Archaeol Archaeosomes When Combined with Different Adjuvants in a Murine Model
Authors:
- Yimei JiaYJYimei Jia
- Bassel AkacheBABassel Akache
- Gerard AgbayaniGAGerard Agbayani
- Vandana ChandanVCVandana Chandan
- Renu DudaniRDRenu Dudani
- Blair A. HarrisonBHBlair A. Harrison
- Lise DeschateletsLDLise Deschatelets
- Usha D. HemrazUHUsha D. Hemraz
- Edmond LamELEdmond Lam
- Sophie RégnierSRSophie Régnier
- Felicity C. StarkFSFelicity C. Stark
- Lakshmi KrishnanLKLakshmi Krishnan
Open Access
- 2 February 2021
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 13 (2) , 205
Abstract
Archaeosomes, composed of sulfated lactosyl archaeol (SLA) glycolipids, have been proven to be an effective vaccine adjuvant in multiple preclinical models of infectious disease or cancer. SLA archaeosomes are a promising adjuvant candidate due to their ability to strongly stimulate both humoral and cytotoxic immune responses when simply admixed with an antigen. In the present study, we evaluated whether the adjuvant effects of SLA archaeosomes could be further enhanced when combined with other adjuvants. SLA archaeosomes were co-administered with five different Toll-like Receptor (TLR) agonists or the saponin QS-21 using ovalbumin as a model antigen in mice. Both humoral and cellular immune responses were greatly enhanced compared to either adjuvant alone when SLA archaeosomes were combined with either the TLR3 agonist poly(I:C) or the TLR9 agonist CpG. These results were also confirmed in a separate study using Hepatitis B surface antigen (HBsAg) and support the further evaluation of these adjuvant combinations.Keywords
This publication has 30 references indexed in Scilit:
- Archaeal lipid vaccine adjuvants for induction of cell-mediated immunityExpert Review of Vaccines, 2016
- CpG-mediated augmentation of CD8+ T-cell responses in mice is attenuated by a water-in-oil emulsion (Montanide ISA-51) but enhanced by an oil-in-water emulsion (IDRI SE)International Immunology, 2016
- Recent Advances of Vaccine Adjuvants for Infectious DiseasesImmune Network, 2015
- Cationic Liposomes Loaded with a Synthetic Long Peptide and Poly(I:C): a Defined Adjuvanted Vaccine for Induction of Antigen-Specific T Cell CytotoxicityThe AAPS Journal, 2014
- CpG ODN and ISCOMATRIX Adjuvant: A Synergistic Adjuvant Combination Inducing Strong T-Cell IFN-ResponsesBioMed Research International, 2013
- Archaeosomes display immunoadjuvant potential for a vaccine against Chagas diseaseHuman Vaccines & Immunotherapeutics, 2013
- Poly(I:C)/Alum Mixed Adjuvant Priming Enhances HBV Subunit Vaccine-Induced Immunity in Mice When Combined with Recombinant Adenoviral-Based HBV Vaccine BoostingPLOS ONE, 2013
- RD Antigen Based Nanovaccine Imparts Long Term Protection by Inducing Memory Response against Experimental Murine TuberculosisPLOS ONE, 2011
- The perfect mix: recent progress in adjuvant researchNature Reviews Microbiology, 2007
- TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)Vaccine, 2005